McNeil “Drug Facts” Booklet Pouch Labeling Proposed For Two-Count Sizes
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer Healthcare is requesting a six-month deferral from the OTC labeling final rule requirements to implement "booklet pouch" labeling for two-count sizes of five products
You may also be interested in...
Novex Pharma labeling deferrals
Canadian private labeler's deferral requests from OTC labeling final rule for Minoxidil Topical Solution 2% (Pharmacia's Rogaine Regular Strength for Men, Rogaine for Women) and Minoxidil Topical Solution 5% For Men (Rogaine Extra Strength for Men) are "appropriate," considering "the time that it has taken to finalize current FDA Drug Facts template labeling," agency says in Feb. 4 correspondence. Letter responds to Novex' Nov. 15 citizen petition. FDA has indicated it will revise the template for the 2% product; no template exists for the 5% version (1"The Tan Sheet" Dec. 10, 2001, p. 3)...
McNeil labeling deferrals
Firm receives six-month deferral from OTC labeling compliance date for 10-count vials of two Tylenol SKUs and two-count pouches of Motrin IB, Tylenol and Imodium products. In Dec. 21 letter, FDA says product labeling must comply with "Drug Facts" requirements by Nov. 16. J&J division originally sought eight-month deferral for vials to allow time for new wrap-around labeling. In November, McNeil requested additional six months to implement "booklet style" labeling on five pouch products (1"The Tan Sheet" Dec. 10, 2001, p. 3)...
Pepcid AC Gelcaps Sample Pouch Deferral Granted Without "Drug Facts" Title
J&J/Merck's request for a nine-month deferral from complying with the OTC labeling format for sample pouches of the company's H2 antagonist Pepcid AC Gelcaps has been granted.